Galectin Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 7, 2023
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of principal executive office) (zip code)
Registrant’s telephone number, including area code: (678 ) 620-3186
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section
12(b) of the Act:
|
Title of each class
|
Trading
Symbol
|
Name of each exchange on which
registered
|
|
|
|
|
| Item 5.07 |
Submission of Matters to a Vote of Security Holders.
|
At the 2023 Annual Meeting of Stockholders held on December 7, 2023, the stockholders of the Company elected each of the Company’s directors that had
been nominated to serve until the next annual meeting or until their successors are elected and have been qualified. The stockholders also:
(1) ratified the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023;
(2) approved an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan.
The final results of the voting on each matter of business at the 2023 Annual Meeting are as follows:
Election of Directors
|
Name
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
|
Gilbert F. Amelio, Ph.D.
|
24,856,340
|
1,155,282
|
18,910,166
|
|
|
Benjamin S. Carson, Sr., M.D.
|
25,523,084
|
488,538
|
18,910,166
|
|
|
Kary Eldred
|
25,603,577
|
408,045
|
18,910,166
|
|
|
Kevin D. Freeman
|
24,969,444
|
1,042,178
|
18,910,166
|
|
|
Joel Lewis
|
25,560,738
|
450,884
|
18,910,166
|
|
|
Gilbert S. Omenn, M.D., Ph.D.
|
25,617,192
|
394,430
|
18,910,166
|
|
|
Marc Rubin, M.D.
|
25,016,122
|
995,500
|
18,910,166
|
|
|
Elissa J. Schwartz, Ph.D.
|
25,615,545
|
396,077
|
18,910,166
|
|
|
Harold H. Shlevin, Ph.D.
|
25,548,431
|
463,191
|
18,910,166
|
|
|
Richard E. Uihlein, Chairman
|
25,593,922
|
417,700
|
18,910,166
|
|
|
Richard A. Zordani
|
25,600,465
|
411,157
|
18,910,166
|
Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023
|
Votes For
|
Votes Against
|
Votes Abstain
|
|
44,481,830
|
252,254
|
187,704
|
Approved an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan.
|
Votes For
|
Votes Against
|
Votes Abstain
|
Broker Non-Votes
|
|
23,901,293
|
1,923,578
|
186,751
|
18,910,166
|
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
| Galectin Therapeutics Inc. | |||
| Date: December 11, 2023 |
By: | /s/ Jack W. Callicutt | |
| Jack W. Callicutt | |||
| Chief Financial Officer | |||
- 3 -